Advances in experimental medicine and biology · 2015
Requirements for Clinical Trials with Gene Therapy and Transplant Products in Switzerland.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marti Andreas
Аннотация
This chapter aims to describe and summarize the regulation of gene and cell therapy products in Switzerland and its legal basis. Product types are briefly described, as are Swiss-specific terminologies such as the term "transplant product," which means products manufactured from cells, tissues, or even whole organs. Although some parts of this chapter may show a guideline character, they are not legally binding, but represent the current thinking of Swissmedic, the Swiss Agency for Therapeutic Products. As so far the experience with marketing approval of gene therapy and cell therapy products in Switzerland is limited, this chapter focuses on the regulation of clinical trials conducted with these products. Quality, nonclinical, and clinical aspects are summarized separately for gene therapy products and transplant products.
Предметные рубрики MeSH
AnimalsCell- and Tissue-Based TherapyClinical Trials as TopicDrug Evaluation, PreclinicalDrug and Narcotic ControlGenetic TherapyHumansInvestigational New Drug ApplicationMarketingPatient SafetyPractice Guidelines as TopicQuality ControlResearch DesignSwitzerlandTissue TransplantationTranslational Research, Biomedical